Published in Diagn Pathol on January 23, 2013
The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors. J Ovarian Res (2013) 0.95
The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer. J Ovarian Res (2013) 0.85
Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders. Afr Health Sci (2014) 0.82
M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients. J Ovarian Res (2015) 0.81
The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer. Biomed Rep (2016) 0.80
Clinical value of serum human epididymis protein 4 assay in the diagnosis of ovarian cancer: a meta-analysis. Onco Targets Ther (2013) 0.78
Overexpression of HE4 (human epididymis protein 4) enhances proliferation, invasion and metastasis of ovarian cancer. Oncotarget (2015) 0.75
Discrepant clinicopathologic characteristics and HE4 performance in type I and type II epithelial ovarian cancer. Int J Clin Exp Med (2015) 0.75
Diagnostic value of urinary-to-serum human epididymis protein 4 ratio in ovarian cancer. Biomed Rep (2017) 0.75
Clinical value of combining transvaginal contrast-enhanced ultrasonography with serum human epididymisprotein-4 and the resistance index for early-stage epithelial ovarian cancer. Saudi Med J (2017) 0.75
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol (2011) 5.53
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med (2008) 5.19
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol (2007) 4.06
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol (2008) 3.54
Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res (2005) 3.41
Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol (2010) 2.71
Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer (2009) 2.48
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol (1994) 2.38
Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol (2005) 2.34
Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol (2006) 2.29
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer (2011) 2.09
A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer (2007) 2.07
Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol (2010) 2.05
HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer (2011) 1.95
The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med (2011) 1.65
Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol (2008) 1.65
Status of tumor markers in ovarian cancer screening. J Clin Oncol (2003) 1.56
Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol (2010) 1.54
Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. Clin Chem Lab Med (2011) 1.50
HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol (2011) 1.50
Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2003) 1.49
WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res (2006) 1.39
No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol (2011) 1.37
Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem (2011) 1.25
Ovarian cancer screening and early detection in the general population. Rev Obstet Gynecol (2011) 1.24
Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer (2004) 1.23
Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res (2003) 1.20
The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal (2009) 1.20
HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta (2011) 1.18
HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn (2009) 1.16
A serum based analysis of ovarian epithelial tumorigenesis. Gynecol Oncol (2008) 1.09
Use of morphology to characterize and manage common adnexal masses. Best Pract Res Clin Obstet Gynaecol (2004) 1.08
Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer (2011) 1.05
Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma. Int J Gynecol Cancer (2011) 1.04
Potential markers for detection and monitoring of ovarian cancer. J Oncol (2011) 1.01
The Eag potassium channel as a new prognostic marker in ovarian cancer. Diagn Pathol (2010) 1.00
Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors. Diagn Pathol (2012) 0.97
Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours. J Surg Oncol (2005) 0.94
Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2009) 0.94
Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol (2011) 0.87
Evaluation of erythrocyte band 3 phosphotyrosine level, glutathione content, CA-125, and human epididymal secretory protein E4 as combined parameters in endometriosis. Fertil Steril (2010) 0.86
Human epididymis protein 4 is a biomarker for transitional cell carcinoma in the urinary system. J Clin Lab Anal (2009) 0.78
Angiotensin converting enzyme DD genotype is associated with development of rheumatic heart disease in Egyptian children. Rheumatol Int (2009) 0.83
Genetic profiling of non-Hodgkin's lymphoma with or without hepatitis C virus infection. Egypt J Immunol (2010) 0.77
Detection of BRCA1 and BRCA2 gene mutation in Egyptian females with breast cancer and their relatives by PCR-SSCP method. Egypt J Immunol (2011) 0.75
Lack of association between endothelial constitutive nitric oxide synthase (ecNOS 4 b/a) gene polymorphism and rheumatic heart disease. Mod Rheumatol (2009) 0.75